Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

Simple Summary Immunotherapy, particularly programmed cell death protein 1 (PD-1) and
programmed death-ligand 1 (PD-L1) inhibitors, has been responsible for changing the …

Introduction Pathologic response has been proposed as an early clinical trial end point of
survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association …

Treatment of non-small-cell lung cancer (NSCLC) has entered the immunotherapy era,
marked by significant survival improvements due to the use of immune checkpoint inhibitors …

Background Neoadjuvant immunotherapy has been demonstrated to be effective and safe in
resectable non-small cell lung cancer (NSCLC) patients. However, the presence of different …

Objective. Epidermal growth factor receptor (EGFR) mutation genotyping plays a pivotal role
in targeted therapy for non-small cell lung cancer (NSCLC). We aimed to develop a …

Abstract Treatment with 3-year of adjuvant osimertinib is considered a new standard in
patients with completely resected stage I-IIIA non-small cell lung cancer (NSCLC) harboring …

Background The patient population with stage III non-small-cell lung cancer (NSCLC) is
heterogeneous, with varying staging characteristics and diverse treatment options. Despite …

Background The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer …

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and
combination immunotherapy and chemotherapy. A majority of these studies excluded …